MSB 2.70% 95.0¢ mesoblast limited

Ann: Change in substantial holding, page-20

  1. 7,171 Posts.
    lightbulb Created with Sketch. 45
    Re "in New Zealand and Canada and the approval is for children and adults." Was there a later announcement than this http://www.asx.com.au/asxpdf/20140429/pdf/42p7qg0gyxdn7q.pdf in particular " Prochymal became the world's first stem cell therapy to be approved in Canada and New Zealand as a first-line treatment for SR-aGVHD in children."? Japan is the market that has it approved in both adults and children I believe.
    Also, I am not sure of the logic with "Obvious it works other wise they would not have purchased Osiris!" Osiris sold it presumably because they felt they should; it failed to meet end points in NZ and Canada . With regards "Mesoblast has moved on with making changes to there technology."; ok, if they have and it is beneficial I guess we will see in time.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.